Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

导出原文传递

翻译打印收藏纠错

作者： Neuen, Brendon L. ^[1] ; Ohkuma, Toshiaki ^[2] ; Neal, Bruce ^[3] ; Matthews, David R. ^[4] ; de Zeeuw, Dick ^[5] ; Mahaffey, Kenneth W. ^[6] ; Fulcher, Greg ^[7] ; Desai, Mehul ; Li, Qiang ; Deng, Hsiaowei ; Rosenthal, Norm ; Jardine, Meg J. ; Bakris, George ; Perkovic, Vlado

作者单位： Janssen Res & Dev LLC, Raritan, NJ USA ^[1] Univ Chicago Med, Chicago, IL USA ^[2] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England ^[3] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands ^[4] Stanford Univ, Sch Med, Stanford Ctr Clin Res, Dept Med, Stanford, CA 94305 USA ^[5] UNSW Sydney, George Inst Global Hlth, POB M201,Missenden Rd, Sydney, NSW 2050, Australia ^[6] Royal North Shore Hosp, Sydney, NSW, Australia ^[7]

关键词 canagliflozin cardiovascular diseases diabetes mellitus type 2 glomerular filtration rate kidney renal insufficiency chronic sodium glucose cotransporter 2 treatment outcome

发布时间 2019-04-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交